Article Versions Notes

Kim G-A, Cho HC, Jeong SW, Kang B-K, Kim M, Jung S, Hwang J, Yoon EL, Jun DW. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease. Pharmaceuticals. 2023; 16(4):623. https://doi.org/10.3390/ph16040623

Kim, Gi-Ae, Hyun Chin Cho, Soung Won Jeong, Bo-Kyeong Kang, Mimi Kim, Seungwon Jung, Jungwook Hwang, Eileen L. Yoon, and Dae Won Jun. 2023. "A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease" Pharmaceuticals 16, no. 4: 623. https://doi.org/10.3390/ph16040623

Kim, G.-A., Cho, H. C., Jeong, S. W., Kang, B.-K., Kim, M., Jung, S., Hwang, J., Yoon, E. L., & Jun, D. W. (2023). A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease. Pharmaceuticals, 16(4), 623. https://doi.org/10.3390/ph16040623